ECSP056232A - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
ECSP056232A
ECSP056232A EC2005006232A ECSP056232A ECSP056232A EC SP056232 A ECSP056232 A EC SP056232A EC 2005006232 A EC2005006232 A EC 2005006232A EC SP056232 A ECSP056232 A EC SP056232A EC SP056232 A ECSP056232 A EC SP056232A
Authority
EC
Ecuador
Prior art keywords
alkyl
aryl
group
het
alkoxy
Prior art date
Application number
EC2005006232A
Other languages
English (en)
Inventor
Alan Stobie
Paul Vincent Fish
Michael Jonathan Fray
Deborah Jane Lovering
Florian Wakenhut
Gavin Alistair Whitlock
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0314048.0A external-priority patent/GB0314048D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP056232A publication Critical patent/ECSP056232A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un compuesto de fórmula (I) y sus derivados farmacéutica y/o veterinariamente aceptables, en la que R1 es un átomo de H, un grupo alquilo de C1-6, un grupo -C(X)Y, un grupo cicloalquilo de C3-8, un grupo arilo, un grupo het, un grupo arilo-alquilo de C1-4, o un grupo het-alquilo de C1-4, en el que los grupos cicloalquilo, arilo o het están opcionalmente sustituidos por al menos un sustituyente independientemente seleccionado de los grupos alquilo de C1-8, alcoxi de C1-8, OH, halo, CF3, OCF3, SCF3, hidroxi-alquilo de C1-6, alcoxi de C1-4-alquilo de C1-6, y alquilo de C1-4-S-alquilo de C1-4; R2 es un grupo arilo o heteroarilo, cada uno opcionalmente sustituido por al menos un sustituyente independientemente seleccionado de los grupos alquilo de C1-8, alcoxi de C1-8, OH, halo, CF3, OCF3, SCF3, hidroxi-alquilo de C1-6, alcoxi de C1-4-alquilo de C1-6, y alquilo de C1-4-S-alquilo de C1-4; R3 es un grupo alquilo de C1-6, cicloalquilo de C3-8, cicloalquilo de C3-8-alquilo de C1-6, arilo, het, arilo-alquilo de C1-4 o het-alquilo de C1-4, en el que los grupos cicloalquilo, arilo o het están opcionalmente sustituidos por al menos un sustituyente independientemente seleccionado de los grupos alquilo de C1-6, alcoxi de C1-6, OH, halo, CF3, OCF3, SCF3, hidroxi-alquilo de C1-6, alcoxi de C1-4-alquilo de C1-6, y alquilo de C1-4-S-alquilo de C1-4; X es un átomo de S o de O; Y es un átomo de H, un grupo alquilo de C1-6, arilo, het, arilo-alquilo de C1-4 o het-alquilo de C1-4; y n es 1 ó 2, siempre que cuando n sea 1, m sea 0 ó 1 y cuando n sea 2, m sea 0, en la que si m es 0, entonces * representa un centro quiral. Los compuestos de la invención exhiben actividad tanto como agentes inhibidores de la reabsorción de la serotonina como de la noradrenalina, y por lo tanto tienen utilidad en una variedad de áreas terapéuticas, por ejemplo, en la incontinencia urinaria.
EC2005006232A 2003-06-17 2005-12-16 Nuevos compuestos ECSP056232A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314048.0A GB0314048D0 (en) 2003-06-17 2003-06-17 Novel compounds
US49312603P 2003-08-06 2003-08-06

Publications (1)

Publication Number Publication Date
ECSP056232A true ECSP056232A (es) 2006-04-19

Family

ID=33554153

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006232A ECSP056232A (es) 2003-06-17 2005-12-16 Nuevos compuestos

Country Status (31)

Country Link
US (2) US7378436B2 (es)
EP (1) EP1638933B1 (es)
JP (1) JP4137159B2 (es)
KR (1) KR100803796B1 (es)
AP (1) AP2005003467A0 (es)
AR (1) AR044715A1 (es)
AT (1) ATE398107T1 (es)
AU (1) AU2004247487B2 (es)
BR (1) BRPI0411594A (es)
CA (1) CA2530159C (es)
CY (1) CY1110434T1 (es)
DE (1) DE602004014372D1 (es)
DK (1) DK1638933T3 (es)
EA (1) EA009881B1 (es)
EC (1) ECSP056232A (es)
ES (1) ES2305776T3 (es)
HR (2) HRP20050993A2 (es)
IL (1) IL172063A0 (es)
IS (1) IS8136A (es)
MA (1) MA27885A1 (es)
MX (1) MXPA05013960A (es)
NL (1) NL1026438C2 (es)
NZ (1) NZ544046A (es)
PA (1) PA8605301A1 (es)
PE (1) PE20050631A1 (es)
PL (1) PL1638933T3 (es)
PT (1) PT1638933E (es)
SI (1) SI1638933T1 (es)
TW (1) TW200505852A (es)
UY (1) UY28360A1 (es)
WO (1) WO2004110995A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100346788C (zh) * 2000-07-31 2007-11-07 尼科梅德丹麦有限公司 用于鼻内给药的芬太尼组合物
EA009881B1 (ru) * 2003-06-17 2008-04-28 Пфайзер Инк. Производные n-пирролидин-3-ил-амида в качестве ингибиторов обратного захвата серотонина и норадреналина
BRPI0516602A (pt) 2004-10-18 2008-09-16 Lilly Co Eli composto, e, composição farmacêutica
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
GB0425766D0 (en) * 2004-11-23 2004-12-22 Pfizer Ltd Novel compounds
US20090239929A1 (en) * 2004-12-14 2009-09-24 Paul Vincent Fish N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors
JP2008523137A (ja) * 2004-12-14 2008-07-03 ファイザー・リミテッド セロトニンおよびノルアドレナリン再取込み阻害剤としてのn−ピロリジン−3−イル−アミド誘導体
TWI439452B (zh) 2005-05-13 2014-06-01 Otsuka Pharma Co Ltd 吡咯烷化合物(二)
KR100962732B1 (ko) 2005-06-02 2010-06-09 에프. 호프만-라 로슈 아게 피페리딘-4-일-아마이드 유도체 및 sst 수용체 아형 5길항제로서 그의 용도
WO2007135530A2 (en) * 2006-05-22 2007-11-29 Pfizer Limited Pharmaceutically & veterinarily suitable salt
US20080014152A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Intranasal delivery of clenbuterol across the cribriform plate and into the brain
JP5219465B2 (ja) * 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
EP2119702A4 (en) * 2007-01-31 2010-12-08 Dainippon Sumitomo Pharma Co amide derivative
JP2010189275A (ja) * 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd ナフタレン誘導体
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
EP2243779A4 (en) * 2007-12-19 2011-04-20 Dainippon Sumitomo Pharma Co HETEROCYCLIC BICYCLIC DERIVATIVE
US7888386B2 (en) 2008-07-24 2011-02-15 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
NZ592413A (en) 2008-11-14 2013-02-22 Theravance Inc Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
EP2419405A1 (en) * 2009-04-15 2012-02-22 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
EP2447264A4 (en) 2009-06-24 2012-12-12 Dainippon Sumitomo Pharma Co N-SUBSTITUTED CYCLIC AMINO DERIVATIVE
WO2011008666A2 (en) 2009-07-13 2011-01-20 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
ES2495366T3 (es) 2009-07-21 2014-09-17 Theravance, Inc. Compuestos de 3-fenoximetilpirrolidina
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 1−(2−フェノキシメチルヘテロアリール)ピペリジン化合物および1−(2−フェノキシメチルヘテロアリール)ピペラジン化合物
US8471040B2 (en) 2010-10-11 2013-06-25 Theravance, Inc. Serotonin reuptake inhibitors
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138773C (es)
US3963745A (en) 1972-04-03 1976-06-15 A. H. Robins Company, Incorporated Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides
US4002757A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides
US4020072A (en) 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
GB1574419A (en) * 1977-11-11 1980-09-03 Anphar Sa Piperidine compounds
CH628885A5 (en) * 1978-01-01 1982-03-31 Anphar Sa Piperidine derivative
US5130312A (en) * 1987-07-17 1992-07-14 Janssen Pharmaceutica N.V. Substituted N-(3-hydroxy-4-piperidinyl)benzamides
FR2642069B1 (fr) 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1997018813A1 (en) 1995-11-22 1997-05-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1999065881A1 (en) 1998-06-19 1999-12-23 Nissan Chemical Industries, Ltd. Heterocyclic compounds as hypoglycemic agents
US6670299B1 (en) * 1999-07-03 2003-12-30 Northwestern University Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
DK1311272T3 (da) 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
NZ520240A (en) * 2000-03-06 2005-04-29 Acadia Pharm Inc Azacyclic compounds for use in the treatment of serotonin related diseases
US7109199B2 (en) 2000-09-22 2006-09-19 Smithkline Beecham Corporation Pyrazolopyridines and pyrazolopyridazines as antidiabetics
BR0113989A (pt) 2000-09-25 2004-01-27 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos
EP1430027B1 (en) 2001-09-14 2010-09-01 High Point Pharmaceuticals, LLC Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
US20050228017A1 (en) 2001-10-31 2005-10-13 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Novel anticancer compounds
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
IL165907A0 (en) * 2002-06-24 2006-01-15 Acadia Pharm Inc N-substituted piperidine derivatives as serotonin receptor agents
AU2003249983A1 (en) 2002-07-18 2004-02-09 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
KR101061352B1 (ko) 2002-12-20 2011-08-31 케모센트릭스 인간 종양-발현된 ccxckr2의 저해물질
EA009881B1 (ru) * 2003-06-17 2008-04-28 Пфайзер Инк. Производные n-пирролидин-3-ил-амида в качестве ингибиторов обратного захвата серотонина и норадреналина

Also Published As

Publication number Publication date
UY28360A1 (es) 2005-01-31
EP1638933A1 (en) 2006-03-29
CA2530159C (en) 2010-02-02
KR20060036927A (ko) 2006-05-02
US7378436B2 (en) 2008-05-27
PL1638933T3 (pl) 2008-10-31
NL1026438C2 (nl) 2005-09-20
IL172063A0 (en) 2009-02-11
MXPA05013960A (es) 2006-02-24
HRP20080339T3 (en) 2008-08-31
KR100803796B1 (ko) 2008-02-14
PT1638933E (pt) 2008-07-22
CY1110434T1 (el) 2015-04-29
PA8605301A1 (es) 2005-02-04
DE602004014372D1 (de) 2008-07-24
PE20050631A1 (es) 2005-09-14
JP4137159B2 (ja) 2008-08-20
AU2004247487B2 (en) 2010-05-20
NZ544046A (en) 2009-08-28
AU2004247487A1 (en) 2004-12-23
AR044715A1 (es) 2005-09-21
ATE398107T1 (de) 2008-07-15
US20050137229A1 (en) 2005-06-23
DK1638933T3 (da) 2008-07-28
AP2005003467A0 (en) 2006-12-31
IS8136A (is) 2005-11-21
EA200501730A1 (ru) 2006-08-25
CA2530159A1 (en) 2004-12-23
NL1026438A1 (nl) 2004-12-20
WO2004110995A1 (en) 2004-12-23
EA009881B1 (ru) 2008-04-28
WO2004110995A8 (en) 2005-04-21
MA27885A1 (fr) 2006-05-02
ES2305776T3 (es) 2008-11-01
SI1638933T1 (sl) 2008-10-31
BRPI0411594A (pt) 2006-08-29
JP2006527758A (ja) 2006-12-07
HRP20050993A2 (en) 2006-03-31
TW200505852A (en) 2005-02-16
EP1638933B1 (en) 2008-06-11
US20080306123A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
ECSP056232A (es) Nuevos compuestos
RS53839B1 (en) SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1
UY26727A1 (es) Derivados de tropano útiles en terapia
NO20092415L (no) Heteromonocyklisk forbindelse og anvendelse derav
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
NO20092692L (no) MAPK/ERK kinaseinhibitorer
JO2935B1 (en) 6- Tertiary azulo pyridazine sulfanil benzothiazole and benzimidazole derivatives, method of preparation, use as pharmaceutical products, pharmaceutical compositions and new use in particular as met inhibitors (methionine)
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR083578A1 (es) INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR083017A1 (es) Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
CO5700747A2 (es) Piperidinas novedosas como moduladores de quimoquina (ccr)
WO2009118473A3 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
ATE413882T1 (de) 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
MY161403A (en) 5- (phenyl/pyridinyl-ethinyl) -2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators
MY146939A (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
CO5660263A2 (es) Derivados de imidazol heteroaril sustituidos como antagonistas del receptor de glutamato
EA200800149A1 (ru) 4,5-диарилпиррольные производные, способ их получения и применение в терапии
MXPA06001039A (es) Derivados de nicotinamida utiles como inhibidores de pde4.
AR083832A1 (es) DERIVADOS DE TETRAHIDROPIRIDO[3,2-F][1,4]OXAZEPIN-8-AMINA PARA EL TRATAMIENTO DE ENFERMEDADES Ab-RELACIONADAS
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
EA201171012A1 (ru) Производные 5-фторбензотиазолов и 5-фторбензимидазолов, содержащие 6-замещенный триазолопиридазинсульфанил в положении 6: получение, применение в качестве лекарственных средств и применение в качестве ингибиторов met
EA200970497A1 (ru) Производные пиррола, их получение и их применение в терапии
NO20071230L (no) Oksazolidinoner inneholdende oksindoler som antibakterielle midler